RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.47%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$563M
AUM Growth
+$563M
(+12%)
Cap. Flow
+$42.6M
Cap. Flow
% of AUM
7.57%
Top 10 Holdings %
Top 10 Hldgs %
30.6%
Holding
102
New
10
Increased
33
Reduced
31
Closed
5
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$13.1M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$11.9M |
| 3 |
Biogen
BIIB
|
$10.2M |
| 4 |
CELG
Celgene Corp
CELG
|
$7.79M |
| 5 |
ENDP
Endo International plc
ENDP
|
$5.85M |
Top Sells
| 1 |
Alkermes
ALKS
|
$11.6M |
| 2 |
STJ
St Jude Medical
STJ
|
$9.9M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
$6.45M |
| 4 |
Labcorp
LH
|
$3.91M |
| 5 |
Perrigo
PRGO
|
$3.72M |
Sector Composition
| 1 | Healthcare | 93.53% |
| 2 | Financials | 1.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
DexCom
DXCM
$30.9B
| $4.36M | 0.77% |
55,000
-20,000
| -27% | -$1.59M |
|
52
AbbVie
ABBV
$374B
| $4.33M | 0.77% |
70,000
-60,000
| -46% | -$3.71M |
|
53
Cooper Companies
COO
$13.3B
| $4.29M | 0.76% |
25,000
-15,000
| -38% | -$2.57M |
|
54
Xencor
XNCR
$594M
| $4.27M | 0.76% |
225,000
+25,000
| +13% | +$475K |
|
55
Bausch Health
BHC
$2.72B
| $4.23M | 0.75% |
210,000
+160,000
| +320% | +$3.22M |
|
|
NVRO
56
DELISTED
NEVRO CORP.
NVRO
| $4.01M | 0.71% |
54,300
+34,300
| +172% | +$2.53M |
|
57
MacroGenics
MGNX
$121M
| $3.78M | 0.67% |
140,000
+20,000
| +17% | +$540K |
|
|
RDUS
58
DELISTED
Radius Health, Inc.
RDUS
| $3.68M | 0.65% |
100,000
-5,000
| -5% | -$184K |
|
59
LivaNova
LIVN
$3.09B
| $3.52M | 0.62% |
70,000
| – | – |
|
|
KITE
60
DELISTED
Kite Pharma, Inc.
KITE
| $3.5M | 0.62% |
+70,000
| New | +$3.5M |
|
61
Abbott
ABT
$230B
| $3.31M | 0.59% |
+84,100
| New | +$3.31M |
|
|
NXTM
62
DELISTED
NxStage Medical Inc.
NXTM
| $3.15M | 0.56% |
+145,300
| New | +$3.15M |
|
|
RVNC
63
DELISTED
Revance Therapeutics, Inc.
RVNC
| $2.99M | 0.53% |
220,000
+50,000
| +29% | +$680K |
|
|
KERX
64
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $2.98M | 0.53% |
450,111
-499,889
| -53% | -$3.31M |
|
|
CEMP
65
DELISTED
Cempra, Inc.
CEMP
| $2.82M | 0.5% |
171,000
| – | – |
|
66
Becton Dickinson
BDX
$54.3B
| $2.54M | 0.45% |
15,000
-10,000
| -40% | -$1.7M |
|
67
Insulet
PODD
$24.2B
| $2.48M | 0.44% |
82,000
| – | – |
|
|
PTLA
68
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $2.48M | 0.44% |
105,000
| – | – |
|
|
NDRM
69
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $2.35M | 0.42% |
+144,546
| New | +$2.35M |
|
70
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $2.22M | 0.39% |
+131,357
| New | +$2.22M |
|
71
Dynavax Technologies
DVAX
$1.19B
| $2.19M | 0.39% |
150,000
| – | – |
|
|
CMRX
72
DELISTED
Chimerix, Inc.
CMRX
| $2.16M | 0.38% |
550,000
+50,000
| +10% | +$197K |
|
73
Halozyme
HALO
$8.75B
| $2.16M | 0.38% |
250,000
-181,000
| -42% | -$1.56M |
|
74
Community Health Systems
CYH
$392M
| $2.11M | 0.37% |
175,000
-50,000
| -22% | -$1.17M |
|
|
ACHN
75
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $2.08M | 0.37% |
266,000
| – | – |
|